Next Article in Journal
Prevalence and Determinants of Antibiotic Self-Medication among Adult Patients with Respiratory Tract Infections in the Mboppi Baptist Hospital, Douala, Cameroon: A Cross-Sectional Study
Next Article in Special Issue
Prevention of Progression in Myopia: A Systematic Review
Previous Article in Journal
Psoriasis and Microbiota: A Systematic Review
Previous Article in Special Issue
Zebrafish Models of Rare Hereditary Pediatric Diseases
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessReview
Diseases 2018, 6(2), 48;

Treatment of Major Depressive Disorder in Pediatric Populations

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN 55902, USA
Mayo Clinic School of Medicine, Mayo Clinic, Rochester, MN 55902, USA
Department of Psychiatry, College of Medicine, Rochester, MN 55902, USA
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Received: 30 April 2018 / Revised: 28 May 2018 / Accepted: 31 May 2018 / Published: 4 June 2018
(This article belongs to the Special Issue Pediatric Diseases)
Full-Text   |   PDF [246 KB, uploaded 4 June 2018]


Major depressive disorder (MDD) is a severe illness that afflicts about 16.6% of people over their lifetime. MDD is highly correlated with suicidality, and often first presents in adolescence. Unfortunately, many pediatric patients suffering from MDD go undiagnosed, and current evidence-based treatment options in the U.S. are limited to psychotherapy and two selective serotonin reuptake inhibitors approved by the United States Food and Drug Administration. Molecular mechanisms have been shown to play a role in MDD pathogenesis, progression, and response to medication, yet few studies have explored the role of these pathways in pediatric MDD. In this review, we outline the gravity and importance of MDD in pediatric patients, some challenges in diagnosis and treatment, current treatments available for pediatric patients, and research to investigate differences between pediatric and adult MDD. We hope that this review will provide an outline of the current understanding and treatment of MDD in pediatric patients, and provide thoughtful insights for future work that could advance our understanding of MDD in pediatric populations, and also identify new therapeutic strategies. View Full-Text
Keywords: major depressive disorder; pediatrics; treatment major depressive disorder; pediatrics; treatment
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Neavin, D.R.; Joyce, J.; Swintak, C. Treatment of Major Depressive Disorder in Pediatric Populations. Diseases 2018, 6, 48.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top